Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

• Published in: Annals of oncology Vol. 14; no. 6; pp. 922 - 930
• Main Authors: Nakagawa, K., Tamura, T., Negoro, S., Kudoh, S., Yamamoto, N., Takeda, K., Swaisland, H., Nakatani, I., Hirose, M., Dong, R.-P., Fukuoka, M.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.06.2003
• Subjects: Administration, Oral; Adult; Aged; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Area Under Curve; Biological and medical sciences; Chemotherapy; Dose-Response Relationship, Drug; EGFR inhibitor; ErbB Receptors - antagonists & inhibitors; Female; Gefitinib; Humans; Iressa; Japan; Key words: efficacy; Male; Medical sciences; Middle Aged; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Pharmacology. Drug treatments; phase I trial; Protein-Tyrosine Kinases - antagonists & inhibitors; Quinazolines - administration & dosage; Quinazolines - adverse effects; Quinazolines - pharmacokinetics; tolerability; Tomography, X-Ray Computed; Treatment Outcome; ZD1839; Asia; Japan; Antineoplastic agent; Human; Solid tumor; Iressa; Enzyme; Transferases; EGFR inhibitor; Oral administration; Enzyme inhibitor; gefitinib; Malignant tumor; Epidermal growth factor receptor; efficacy; Blood plasma; Chemotherapy; Growth factor receptor; Epidermal growth factor; Treatment; Phase I trial; phase I trial tolerability; Pharmacokinetics; Protein-tyrosine kinase; ZD1839

Background: This phase I dose-escalating study investigated the tolerability and toxicity of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid tumors. Thirty-one patients were included. Patients and methods: Patients...